Your cart is empty
Add prompt packs to continue
This definitive collection of dermatology prompts represents the cutting edge in clinical care powered by artificial intelligence. Meticulously designed for the modern dermatologist, this repository transforms daily practice by streamlining everything from the documentation of complex medical histories to the detailed analysis of rare pathologies, enabling unprecedented diagnostic accuracy and more agile case management. By integrating these prompts into their workflow, specialists are able to standardize therapeutic protocols, improve communication with the patient, and systematically deepen the clinico-pathological correlation. It is the essential tool to raise the standard of skin care, reducing the administrative burden while promoting excellence in medical, surgical and aesthetic treatment.
100 resources included
He acts as a specialist in Dermatology with extensive experience in the management of erythematous-desquamative dermatoses. Your task is to develop a comprehensive clinical management protocol for a patient with suspected pityriasis rosea Gibert (PRG), integrating the most recent evidence and international clinical practice guidelines to optimize the diagnostic and therapeutic process. It begins by analyzing the morphology of the initial lesions, with special emphasis on the identification and description of the 'heraldic stain' or initial medallion, detailing its location in [Anatomical location] and its chronological evolution towards the secondary eruption. You must consider the pathognomonic characteristics such as the 'Christmas tree' distribution pattern following the Blaschko lines and the presence of the internal scaly collarette, adjusting the analysis to a patient of [Patient Age] years with a current evolution time of [Weeks of evolution] weeks. Develop an exhaustive differential diagnosis that is critical to rule out pathologies that mimic this condition. It is imperative to include and differentiate PRG from secondary syphilis (requesting serological tests if there is palmoplantar involvement or risk factors), tinea corporis, guttate psoriasis, pityriasis lichenoides chronica and pityriasiform pharmacodermas. For this specific case, integrate into your reasoning that the patient presents [Associated symptoms such as severe itching or general discomfort] and any relevant history of previous respiratory infection. Design a stepped and personalized therapeutic plan. It begins with general patient education measures about the benign and self-limiting nature of the disease. Then, it proposes pharmacological options based on severity: from the use of emollients and medium-potency topical corticosteroids to control pruritus, to the justified consideration of systemic antivirals (such as Acyclovir) if started in early phases, or narrow-band UVB phototherapy in extensive cases, taking into account that the patient has [Comorbidities or contraindications]. Finally, it establishes the prognosis and the dermatological follow-up plan. It clearly indicates the warning signs for which the patient should return for consultation, the estimated time for complete resolution of the lesions without leaving a scar (although mentioning the risk of post-inflammatory hyperpigmentation or hypopigmentation) and the low probability of recurrence, structuring the information clearly for its inclusion in the electronic medical record.
He acts as a doctor specializing in Dermatology with high expertise in Clinical Onicology and management of chronic inflammatory diseases. Your objective is to design a detailed and personalized systemic therapeutic protocol for a patient diagnosed with moderate to severe nail psoriasis who presents a significant impact on quality of life and lack of response to previous topical therapies. To contextualize the case, consider a patient of [Age] years, with a picture of nail psoriasis that affects [Number of nails] nails, presenting clinical signs such as oil papules, distal onycholysis, subungual hyperkeratosis and [Other signs such as pittings or leukonychia]. It is essential that you determine the severity using the estimated Nail Psoriasis Severity Index (NAPSI) of [NAPSI Score] and evaluate the presence of concomitant psoriatic arthritis in [Joints affected or 'None']. Develops an in-depth technical comparison between conventional systemic treatment options, including Methotrexate, Cyclosporin, Acitretin and Apremilast. For each drug, you must detail: 1) Specific mechanism of action in the nail unit; 2) Recommended dosage to optimize penetration into the matrix and nail bed; 3) Expected time of initial and maximum clinical response (considering the slow growth cycle of the nail); and 4) Laboratory monitoring protocol (hemogram, liver, kidney profile). Subsequently, it analyzes the transition or primary choice towards biological therapies in case the patient meets severity or refractoriness criteria. Evaluates the efficacy reported in recent medical literature for IL-17 inhibitors (such as Secukinumab or Ixekizumab), IL-23 inhibitors (such as Guselkumab or Risankizumab), and TNF-alpha inhibitors. Prioritizes those drugs that have demonstrated greater clearance of NAPSI in phase III clinical trials specifically aimed at the nail unit. The protocol concludes by establishing a follow-up plan for [Number of months] months, therapeutic success criteria, management of possible systemic adverse effects and recommendations for complementary care for the maintenance of the nail barrier. It integrates the reference bibliography of the guides of the Spanish Academy of Dermatology and Venereology (AEDV) or the Psoriasis Group (Grupso).
He acts as an expert consultant in Medical Dermatology and Advanced Pharmacotherapy. Your goal is to develop a comprehensive therapeutic plan for [Name of the inflammatory or autoimmune pathology, e.g. Bullous pemphigoid] focused on the implementation and management of systemic corticosteroid-sparing agents. The patient is currently receiving [Current dose of corticosteroid, e.g. Prednisone 1 mg/kg/day] and a safe transition strategy is required to mitigate the adverse effects of chronic steroid use, such as osteoporosis, adrenal suppression, and iatrogenic Cushing's syndrome. First, perform a comparative analysis and justify the choice of the most appropriate sparing agent among the following options: [Option A: Methotrexate, Option B: Azathioprine, Option C: Mycophenolate mofetil, Option D: Cyclosporine]. You should base your recommendation on the safety profile, the patient's comorbidities ([Comorbidities, e.g. Hypertension, Diabetes, Kidney Failure]), and the most recent scientific evidence in dermatology. It details the prerequisites for starting treatment, including serology for hepatitis, quantiferon for TB, and baseline organ function assessments depending on the drug chosen. Second, design a dynamic and personalized dosing scheme. For the selected sparing agent, specify the starting dose, the gradual increase (titration), and the expected maintenance dose based on the patient's weight and response. At the same time, it establishes a corticosteroid reduction schedule (tapering), indicating at what exact moment to start the taper (consolidation phase) and under what strict clinical parameters (e.g. absence of new lesions or control of pruritus during a certain period). Finally, it integrates safety monitoring and toxicity management protocols. It includes critical laboratory thresholds that require temporary suspension or reduction of corticosteroid sparing, such as leukopenia levels, elevated transaminases or creatinine alteration. Provides guidance on necessary supplementation (e.g. folic acid in methotrexate) and prophylactic measures. The final result should be a structured protocol that the dermatologist can use as a reference for the bimonthly or quarterly clinical follow-up of the patient transitioning to monotherapy with savers.